Wave Life Sciences, Inc.
WVEHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeWave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. At a $626.6M market cap, Wave Life Sciences, Inc. ranks as a small-cap company within healthcare. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Market Cap
$626.6M
Beta
-1.43
P/E (TTM)
—
P/E (Fwd)
-2.73
EPS (TTM)
$-1.08
EPS (Fwd)
$-1.17
ROE
-67.4%
ROA
-33.6%
Cash
$490.6M
Total Debt
$43.6M
Free CF
-$128.8M
52W Change
-58.3%
Annual Financials
Cash vs Debt
Where WVE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, WVE finished 47.34% below its 150-day moving average ($6.02) and 60.03% below its 200-day moving average ($7.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WVE overbought or oversold?
At the October 20, 2026 close, WVE's RSI(14) was 31.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Wave Life Sciences, Inc. holds $490.6M in cash against $43.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$128.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -67.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $41.0M (2021) to $42.7M (2025).
With a beta below 0.7, Wave Life Sciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, WVE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing WVE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.